111 Capital’s Eli Lilly LLY Stock Holding History

111 Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.56M	Buy	2,786 +756	+37%	+$766K	0.63%	27
2025 Q4	$2.18M	Buy	2,030 +1,376	+210%	+$1.32M	0.48%	32
2025 Q3	$499K	Sell	654 -864	-57%	-$643K	0.09%	217
2025 Q2	$1.18M	Sell	1,518 -1,403	-48%	-$1.09M	0.2%	110
2025 Q1	$2.41M	Buy	+2,921	New	+$2.43M	0.47%	38

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

111 Capital's LLY Position: Q1 2026 in Review

111 Capital increased its Eli Lilly (LLY) stake by 37% in Q1 2026, buying an estimated $766K and bringing the position to 2,786 shares worth $2.56M. The position accounts for 0.63% of the portfolio, ranked #27.

111 Capital first reported a position in LLY in Q1 2025 and has held it in 5 quarters since. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

111 Capital held 2,786 shares of Eli Lilly worth $2.56M as of Q1 2026.
111 Capital bought 756 Eli Lilly shares in Q1 2026, an estimated $766K.
Eli Lilly made up 0.63% of 111 Capital's portfolio in Q1 2026, its #27 holding.
111 Capital first reported a position in Eli Lilly in Q1 2025 and has held it in 5 quarters since.
4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on 111 Capital's 13F filing for Q1 2026, filed 11 May 2026.